Immune Design (IMDZ) Receives Coverage Optimism Score of 0.09

Press coverage about Immune Design (NASDAQ:IMDZ) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Immune Design earned a news impact score of 0.09 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 46.1235922521092 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:

IMDZ has been the subject of a number of recent research reports. Cowen reissued a “buy” rating on shares of Immune Design in a research report on Monday, December 11th. Wells Fargo & Co downgraded shares of Immune Design from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $29.00 to $10.00 in a research report on Tuesday, October 17th. ValuEngine downgraded shares of Immune Design from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 21st. Finally, Zacks Investment Research downgraded shares of Immune Design from a “buy” rating to a “hold” rating in a research report on Friday, November 10th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $13.06.

Shares of Immune Design (NASDAQ IMDZ) traded up $0.05 during mid-day trading on Friday, hitting $3.65. 394,179 shares of the stock were exchanged, compared to its average volume of 536,863. Immune Design has a 12-month low of $3.50 and a 12-month high of $13.05. The company has a market cap of $173.01, a P/E ratio of -1.71 and a beta of 2.36.

Immune Design (NASDAQ:IMDZ) last issued its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($0.52) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.11. Immune Design had a negative net margin of 619.62% and a negative return on equity of 68.69%. The firm had revenue of $0.52 million during the quarter, compared to the consensus estimate of $0.62 million. equities research analysts expect that Immune Design will post -1.89 earnings per share for the current year.

In other news, major shareholder Leo Guthart bought 10,000 shares of the stock in a transaction that occurred on Thursday, October 19th. The shares were bought at an average price of $6.09 per share, for a total transaction of $60,900.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Peter Svennilson bought 2,681,000 shares of the stock in a transaction that occurred on Friday, October 27th. The shares were purchased at an average price of $4.10 per share, for a total transaction of $10,992,100.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 5,310,000 shares of company stock worth $21,855,900 and have sold 13,959 shares worth $58,209. 20.70% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.thelincolnianonline.com/2018/01/13/immune-design-imdz-receives-coverage-optimism-score-of-0-09.html.

About Immune Design

Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.

Insider Buying and Selling by Quarter for Immune Design (NASDAQ:IMDZ)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply